Fagotti, Anna http://orcid.org/0000-0001-5579-335X
Ferrandina, Maria Gabriella
Vizzielli, Giuseppe
Pasciuto, Tina
Fanfani, Francesco
Gallotta, Valerio
Margariti, Pasquale Alessandro
Chiantera, Vito
Costantini, Barbara
Gueli Alletti, Salvatore
Cosentino, Francesco
Scambia, Giovanni
Clinical trials referenced in this document:
Documents that mention this clinical trial
Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
https://doi.org/10.1136/ijgc-2021-003313
Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-004249
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)
https://doi.org/10.1136/ijgc-2022-004101
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640
Low-grade serous ovarian cancer: expert consensus report on the state of the science
https://doi.org/10.1136/ijgc-2023-004610
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
https://doi.org/10.1136/ijgc-2023-004624
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
https://doi.org/10.1016/j.ejca.2016.01.017
Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081
REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295
Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept
https://doi.org/10.1016/j.ygyno.2015.07.095
Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
https://doi.org/10.1016/j.ygyno.2013.08.005
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer
https://doi.org/10.1136/ijgc-2021-003320
Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
https://doi.org/10.1016/j.ygyno.2015.03.049
Documents that mention this clinical trial
Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
https://doi.org/10.1136/ijgc-2021-003313
Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-004249
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)
https://doi.org/10.1136/ijgc-2022-004101
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640
Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
https://doi.org/10.1136/ijgc-2023-004624
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
Low-grade serous ovarian cancer: expert consensus report on the state of the science
https://doi.org/10.1136/ijgc-2023-004610
Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
https://doi.org/10.1016/j.ejca.2016.01.017
REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295
Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept
https://doi.org/10.1016/j.ygyno.2015.07.095
Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
https://doi.org/10.1016/j.ygyno.2013.08.005
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer
https://doi.org/10.1136/ijgc-2021-003320
Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
https://doi.org/10.1016/j.ygyno.2015.03.049
Documents that mention this clinical trial
Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676
Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
https://doi.org/10.1136/ijgc-2022-004249
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)
https://doi.org/10.1136/ijgc-2022-004101
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer
https://doi.org/10.1136/ijgc-2021-003313
Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
https://doi.org/10.1136/ijgc-2023-004624
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
Low-grade serous ovarian cancer: expert consensus report on the state of the science
https://doi.org/10.1136/ijgc-2023-004610
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome
https://doi.org/10.1016/j.ejca.2016.01.017
Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081
REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295
Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: Proof of a concept
https://doi.org/10.1016/j.ygyno.2015.07.095
Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: Impact on prognosis in a single institution experience
https://doi.org/10.1016/j.ygyno.2013.08.005
Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
https://doi.org/10.1016/j.ygyno.2015.03.049
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer
https://doi.org/10.1136/ijgc-2021-003320
Documents that mention this clinical trial
Tumor biology and impact on timing of surgery in advanced epithelial ovarian cancer
https://doi.org/10.1136/ijgc-2023-004676
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)
https://doi.org/10.1136/ijgc-2020-001640
Neoadjuvant chemotherapy for advanced ovarian cancer: the tail of the scorpion for radical debulking surgery?
https://doi.org/10.1136/ijgc-2020-002081
REPLY: SCORPION study: is it time to call primary debulking surgery superior?
https://doi.org/10.1136/ijgc-2020-002295
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)
https://doi.org/10.1136/ijgc-2019-000682
2022-RA-798-ESGO Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II)
https://doi.org/10.1136/ijgc-2022-esgo.562
Funding for this research was provided by:
Fondazione Policlinico Universitario A. Gemelli, IRCCS (5750827)